Trial record 1 of 58 for: "Clear Cell Renal Cell Carcinoma" | "Protein Kinase Inhibitors"
Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00727532|
Recruitment Status : Terminated (Low Accrual)
First Posted : August 4, 2008
Results First Posted : May 3, 2019
Last Update Posted : May 3, 2019
National Cancer Institute (NCI)
Information provided by (Responsible Party):
|Study Design||Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment|
Hereditary Clear Cell Renal Cell Carcinoma
|Recruitment Details||Study was open to enrollment at Northwestern University beginning June 2008, and closed to enrollment in September 2012.|
The trial did not reach the original goal of 10 subjects. Only 9 out of 10 patients had been enrolled, with no accrual for a period of more than 1 year. Therefore it was administratively closed by the Data Monitoring Committee.